GPRC5D and neoplasm: Dysgeusia and nail toxicities likely result from on-target, off-tumor effects, as GPRC5D is expressed in filiform papillae (lacking taste receptors) and residential plasma cells in the oral cavity [22], as well as in the nail keratogenous zone in preclinical models [23].